原发性IgA肾病的治疗研究进展

打开文本图片集

[Abstract] IgA Nephropathy （IgAN） is the most common primary glomerular disease worldwide，and its pathological mechanism revolves aroundthe binding of circulating immune complexes containing IgA to mesangial cels，leading tosecondaryglomerularinflammationandtubulointerstitial fibrosis.Foralong time，clinicaltherapy for IgAN has mainly focused on symptomatic supportive treatment and systemic application of glucocorticoids，but a considerable proportion of patients still progressto end-stage renal disease （ESRD）.With a deeper understanding of the pathogenesis of IgAN，new therapeutic targets and drugs are being developed，including blockadeof the endothelin system，targeted therapyof the intestinal mucosal immune systemand Bcels，and complement inhibition. This review provides an overview of current， recently approved，and emerging IgAN treatment methods.

[Keywords] IgA nephropathy Non-immunotherapy Immunosuppression Targeted therapy 'omplement

First-author'saddres：DepartmentofNephrology，Binzhou MedicalUniversityHospital，inzhot 56600，China

doi：10.3969/j.issn.1674-4985.2025.21.038

IgA肾病（IgAnephropathy，IgAN）是全球最常见的原发性肾小球疾病，也是慢性肾脏病（chronickidney disease，CKD）和终末期肾脏病（end-stagerenaldisease，ESRD）的主要原因之一。（剩余11905字）